These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 25902334)

  • 1. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
    Huang L; Counter CM
    PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased tumorigenesis in mice with a Kras point mutation at C118.
    Huang L; Carney J; Cardona DM; Counter CM
    Nat Commun; 2014 Nov; 5():5410. PubMed ID: 25394415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis.
    Counter C
    Redox Biol; 2015 Aug; 5():417. PubMed ID: 28162280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
    Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
    Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of liver oncogenic potential among human RAS isoforms.
    Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW
    Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
    Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
    Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
    Nussinov R; Zhang M; Tsai CJ; Jang H
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation Of Wild-Type Hras Suppresses The Earliest Stages Of Pancreatic Cancer.
    Weyandt J
    Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth.
    Tang R; Shuldiner EG; Kelly M; Murray CW; Hebert JD; Andrejka L; Tsai MK; Hughes NW; Parker MI; Cai H; Li YC; Wahl GM; Dunbrack RL; Jackson PK; Petrov DA; Winslow MM
    Nat Cell Biol; 2023 Jan; 25(1):159-169. PubMed ID: 36635501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
    Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
    Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoform-Specific Effects of Wild-Type Ras Genes on Carcinogen-Induced Lung Tumorigenesis in Mice.
    Weyandt JD; Carney JM; Pavlisko EN; Xu M; Counter CM
    PLoS One; 2016; 11(12):e0167205. PubMed ID: 27911940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.
    Weyandt JD; Lampson BL; Tang S; Mastrodomenico M; Cardona DM; Counter CM
    PLoS One; 2015; 10(10):e0140253. PubMed ID: 26452271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A model for RAS mutation patterns in cancers: finding the sweet spot.
    Li S; Balmain A; Counter CM
    Nat Rev Cancer; 2018 Dec; 18(12):767-777. PubMed ID: 30420765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
    Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.
    Adhikari H; Kattan WE; Kumar S; Zhou P; Hancock JF; Counter CM
    Nat Commun; 2021 Sep; 12(1):5248. PubMed ID: 34504076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activating
    Shirazi F; Jones RJ; Singh RK; Zou J; Kuiatse I; Berkova Z; Wang H; Lee HC; Hong S; Dick L; Chattopadhyay N; Orlowski RZ
    Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20004-20014. PubMed ID: 32747568
    [No Abstract]   [Full Text] [Related]  

  • 17. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.
    Felisiak-Goląbek A; Inaguma S; Kowalik A; Wasąg B; Wang ZF; Zięba S; Pięciak L; Ryś J; Kopczynski J; Sarlomo-Rikala M; Góźdź S; Lasota J; Miettinen M
    Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):40-45. PubMed ID: 29206715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.
    Huang X; Schwind S; Santhanam R; Eisfeld AK; Chiang CL; Lankenau M; Yu B; Hoellerbauer P; Jin Y; Tarighat SS; Khalife J; Walker A; Perrotti D; Bloomfield CD; Wang H; Lee RJ; Lee LJ; Marcucci G
    Oncotarget; 2016 Sep; 7(37):59273-59286. PubMed ID: 27517749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Nrf2 on tumour growth and drug sensitivity in oncogenic K-ras-transformed cells in vitro and in vivo.
    Shao J; Glorieux C; Liao J; Chen P; Lu W; Liang Z; Wen S; Hu Y; Huang P
    Free Radic Res; 2018 Jun; 52(6):661-671. PubMed ID: 29621903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.
    Grabocka E; Pylayeva-Gupta Y; Jones MJ; Lubkov V; Yemanaberhan E; Taylor L; Jeng HH; Bar-Sagi D
    Cancer Cell; 2014 Feb; 25(2):243-56. PubMed ID: 24525237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.